The Future of Psychedelic Medicine with Ismail Lourido Ali, JD

In the 200th episode of the Psychedelic Medicine Podcast, Ismail Lourido Ali, JD joins to discuss the future of psychedelic medicine. Ismail serves as MAPS Co-Executive Director and has been actively participating in the drug policy reform movement for over a decade, informed by half a lifetime of diverse personal experience with psychedelics and other substances.

In this conversation, Ismail explores the rapidly evolving landscape of psychedelic medicine, reflecting on the field's major milestones, challenges, and future possibilities. He discusses how public perception has shifted over the past decade, the role of state-level psychedelic reforms, and the tensions created by commercialization, overhype, and competing regulatory models. Much of the discussion focuses on the recent federal executive order related to psychedelic research and drug development, including what it may mean for FDA approval timelines, right-to-try access, rescheduling, and public health standards. Throughout, Ismail emphasizes that psychedelics are not a "silver bullet," but tools that require strong systems of care, thoughtful policy, and community support to be integrated responsibly into healthcare and society.

In this episode, you'll hear:

• How public attitudes toward psychedelics have shifted over the past decade
• Major milestones that expanded psychedelic policy reform beyond federal drug approval
• The promises and pitfalls of increased visibility, commercialization, and hype in the psychedelic field
• What the recent federal executive order on psychedelics actually does and does not do
• An explanation of right-to-try laws, FDA approval pathways, and the complexities of rescheduling psychedelic medicines
• Why maintaining rigorous evidentiary standards is essential for the long-term credibility of psychedelic medicine
• MAPS' vision for the future of psychedelic access, including regulated adult use, professional education, and community safety infrastructure
• How psychedelic policy reform could evolve to include broader systems of mental health care, crisis response, and social healing

Quotes:

"[Federal funding for psychedelic research] will only be so effective unless there is a massive reinvestment in mental health, harm reduction, and social services that actually ground—and one could say integrate—this medicine into like the continuum of care and the fabric of community that people are actually in." [25:07]

"Even though those of us in the psychedelic advocacy field do want to see drugs like MDMA and others be approved by the FDA for medical use in these controlled clinical settings… At the same time, we don't want medical access to be accelerated so much that it's at the expense of public health or consumer protection or an evidentiary standard that other drugs are being held to." [37:59]

"Medical professionals are not just prescribing things because they're approved. Many of them want to look at the evidence themselves. They want to look at the clinical trials. They want to understand 'is this the right choice for my patient?' But you can only know if [psychedelics] are being held to a comparable standard." [39:31]

"What's MAPS' vision for ten years from now or 40 years from now for that matter? I like to think of it as lots of on ramps and lots of off ramps. It's that people who are seeking access to psychedelics for any beneficial purpose—for their own treatment or healing, for their own spiritual growth, for their personal development, for their for improving of their relationships with their loved ones or with nature or with spirituality, whatever that cosmology is that they hold—that they have safe, responsible methods of doing so." [44:47]

Links:

Ismail on Instagram

Psychedelic Medicine Association

Porangui